查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1950545

犬庫欣氏症治療市場依藥物類別、治療類型、給藥途徑及通路分類，全球預測（2026-2032年）

Treating Cushing's Disease in Dogs Market by Drug Class, Treatment Type, Administration Route, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025 年犬庫欣氏症治療市場價值為 4.7291 億美元，預計到 2026 年將成長至 5.2731 億美元，年複合成長率為 9.50%，到 2032 年將達到 8.9274 億美元。

關鍵市場統計數據
基準年 2025 4.7291億美元
預計年份：2026年 5.2731億美元
預測年份 2032 8.9274億美元
複合年成長率 (%) 9.50%

本書以清晰易懂的臨床數據為基礎，對犬庫欣氏症進行了介紹，說明了診斷的複雜性、治療決策過程以及相關人員的優先事項。

犬高腎上腺皮質功能亢進症，俗稱犬庫欣氏症，是一種複雜的內分泌疾病，其特徵是循環中糖皮質激素長期過量。此症候群主要由兩種生物學途徑引起：腦下垂體依賴性疾病，即促腎上腺皮質激素（ACTH）分泌腺瘤導致ACTH水平升高；以及腎上腺依賴性疾病，即自主性腎上腺病變導致皮質醇過量。臨床症狀因疾病階段和病因而異，包括多尿、煩渴、皮膚改變、腹脹、肌肉萎縮以及多種代謝併發症，這些都會降低犬隻的生活品質並加重合併症。

診斷技術的進步、治療方法的改進以及數位化護理模式如何改變犬庫欣氏症的治療模式

犬庫欣氏症的治療格局正經歷著諸多變革，這主要得益於診斷技術的進步、治療方法的不斷發展以及犬主與飼主護理參與度的提高。在診斷方面，檢測靈敏度的提高和內分泌檢測的廣泛應用縮短了許多患者的診斷時間。內科專家和實驗室之間的跨學科合作也使結果解讀框架更加標準化。同時，藥物創新正朝著改善製劑和給藥策略的方向發展，以提高藥物的耐受性和依從性，並日益重視在長期管理中平衡療效和安全性的實證治療通訊協定。

評估關稅調整對犬內分泌治療藥物供應鏈、分銷網路和臨床獲取途徑的連鎖反應

貿易政策的發展，包括關稅調整，會對整個獸藥生態系統產生切實的連鎖反應，而供應鏈韌性、成本轉嫁動態以及分銷調整對於全面評估其累積影響至關重要。進口關稅的變化會影響原料藥、藥品、包裝材料或輔助設備，使依賴跨國供應商的製造商和契約製造製造商的採購變得複雜。因此，採購團隊可能會重新評估其供應商組合，優先考慮國內或區域供應商，並重新談判長期合約以降低波動性。

將臨床和商業性重點與藥物類別、治療方法、給藥途徑和分銷管道聯繫起來的深入細分分析

細分市場層面的清晰分類對於理解治療趨勢以及使商業策略與臨床使用模式保持一致至關重要。依藥物類別分類，我們評估Ketoconazole、米托坦和曲洛司坦三種治療方案，每種方案的作用機制、安全性特徵和長期監測要求各不相同。根據治療類型，決策分為藥物治療和手術治療。藥物治療包括Ketoconazole、米托坦和曲洛司坦，外科上的照護的特徵是腎上腺切除術和腦下垂體切除術，需要專業的手術技巧和手術全期支持。根據給藥途徑，給藥途徑包括注射和口服。注射給藥進一步分為肌肉注射和靜脈注射，而口服給藥通常以膠囊或錠劑的形式出現，這會影響偏好、劑量準確性和飼主的依從性。根據通路，藥物的供應和可及性取決於線上藥房、零售藥房和獸醫診所，每種管道都有其獨特的監管、物流和客戶體驗方面的考慮。

區域趨勢和醫療基礎設施差異會影響全球獸醫市場的診斷取得、治療方法採用和分銷策略。

區域因素是醫療服務模式、法規環境和商業性趨勢的關鍵決定因素，因此了解區域差異對產業計畫至關重要。在美洲，成熟的獸醫基礎設施、廣泛的臨床網路以及寵物保險普及率的提高，為較高的診斷率和慢性病持續管理提供了保障。同時，競爭激烈的通路和成熟的電子商務生態系統也為飼主和診所提供了多種採購途徑。在歐洲、中東和非洲地區，監管的異質性和人均獸醫資源的差異造就了多元化的市場環境，都市區領先獲得專業的外科手術服務，而農村地區則更依賴醫療管理和藥房服務。監管協調工作和跨境獸醫合作正在影響該地區製造商的打入市場策略和上市後監管實踐。在亞太地區，寵物擁有量的快速成長、都市化的加快以及可支配收入的提高，正在推動對先進獸醫服務的需求。然而，臨床能力和物流基礎設施方面仍然存在差距，影響了口服療法和外科手術干預的相對採用率，並推動了遠端醫療和線上分銷領域的創新。

企業的競爭和策略重點在於平衡醫療最佳化、臨床醫生協作和分銷彈性。

犬庫欣氏症治療領域的競爭格局呈現出成熟藥物、不斷演進的製劑策略以及以服務為導向的差異化優勢並存的局面。該領域的企業致力於最佳化產品特性，例如耐受性、給藥便利性和穩定性，同時增加對配套資源的投入，例如教育計畫、臨床決策支援工具以及與核心療法相輔相成的患者依從性管理平台。此外，一些業內相關人員正在探索製劑創新，以改善偏好並實現小規模患者群體的精準給藥，從而解決合併症較多的患者群體在用藥依從性方面面臨的挑戰。

為製造商和服務供應商提供切實可行的跨職能方法，以改善獸醫領域的患者療效、增強供應鏈韌性並提高商業性效率。

致力於改善犬庫欣氏症治療並提升商業性效益的產業領導者應在產品、服務和營運等多個領域進行一系列合作。首先，應優先投資於臨床醫生教育和決策支援工具，以減少診斷延誤，並促進在內科和外科治療方案選擇中採用實證醫學方法。這些措施也有助於合理利用治療手段，同時提升治療方法的安全性。其次，應實現採購和物流多元化，以降低貿易政策變化和供應中斷帶來的風險。這包括簽訂多供應商協議，並評估現有的區域生產和契約製造方案。

一項結合醫療保健專業人員訪談、監管審查和資料三角驗證的穩健的混合方法研究設計將檢驗醫療保健服務的趨勢和實際意義。

我們的研究途徑結合了定性和定量方法，以確保分析的嚴謹性和實際應用價值。主要研究包括對執業獸醫、專科外科醫生、診斷實驗室主任和分銷合作夥伴進行結構化訪談，以收集他們對診斷、治療方案和獲取障礙的實地觀點。次要研究則利用同行評審的獸醫學文獻、臨床指南文件、監管出版刊物和開放的臨床試驗註冊庫，綜合現有的臨床知識，並為新興治療方法提供背景資訊。

總之，我們強調需要採取臨床、商業性和運作策略相結合的綜合方法來改善患有庫欣氏症的犬隻的治療效果。

總之，犬庫欣氏症的治療涉及內分泌學、藥理學和臨床服務等多個領域，該領域的進展依賴於臨床創新與實踐的融合。診斷技術的改進和治療方法的最佳化為改善長期治療效果提供了機會。然而，要充分發揮這些潛力，需要包括生產商、經銷商、診所和監管相關人員在內的相關人員的共同努力。面對貿易政策和採購管道的中斷，供應鏈的韌性和適應性分銷策略至關重要。同時，有針對性的臨床醫生教育和以患者為中心的產品設計可以減少治療依從性的障礙，並提高患病動物的生活品質。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 犬庫欣氏症治療藥物市場

  • Ketoconazole
  • 米托坦
  • 特里洛斯坦

9. 犬庫欣氏症治療市場（依治療方法）

  • 醫療
    • Ketoconazole
    • 米托坦
    • 特里洛斯坦
  • 手術治療
    • 腎上腺切除術
    • 腦下垂體切除術

10. 犬庫欣氏症治療市場（依給藥途徑分類）

  • 注射
    • 肌肉內注射
    • 靜脈注射
  • 口服
    • 膠囊
    • 藥片

第11章 犬庫欣氏症治療市場（依通路分類）

  • 網路藥房
  • 零售藥房
  • 獸醫診所

12. 各地區犬庫欣氏症治療市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 犬庫欣氏症治療市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

14. 各國犬庫欣氏症治療市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

15. 美國犬庫欣氏症治療市場

第16章 中國犬庫欣氏症治療市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Bayer AG
  • Bimeda, Inc.
  • Boehringer Ingelheim Animal Health USA Inc.
  • Ceva Sante Animale
  • Chanelle Pharma Group
  • Covetrus, Inc.
  • Dechra Pharmaceuticals PLC
  • Elanco Animal Health Incorporated
  • Heska Corporation
  • IDEXX Laboratories, Inc.
  • Kyoritsu Seiyaku Corporation
  • Merck & Co., Inc.
  • Nippon Zenyaku Kogyo Co., Ltd.
  • Vetoquinol SA
  • Virbac SA
  • Vetoquinol
  • Zoetis Inc.
Product Code: MRR-4F7A6D4FD8D0

The Treating Cushing's Disease in Dogs Market was valued at USD 472.91 million in 2025 and is projected to grow to USD 527.31 million in 2026, with a CAGR of 9.50%, reaching USD 892.74 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 472.91 million
Estimated Year [2026] USD 527.31 million
Forecast Year [2032] USD 892.74 million
CAGR (%) 9.50%

A clear and clinically grounded introduction to canine Cushing's disease explaining diagnostic complexity, therapeutic decision pathways, and stakeholder priorities

Canine hyperadrenocorticism, commonly referred to as Cushing's disease in dogs, represents a complex endocrine disorder characterized by chronic excess circulating glucocorticoids. The syndrome arises primarily through two biological pathways: pituitary-dependent disease, where a corticotroph adenoma drives elevated adrenocorticotropic hormone levels, and adrenal-dependent disease, where autonomous adrenal lesions produce excess cortisol. Clinical presentation varies by stage and etiology and commonly includes polyuria, polydipsia, dermatologic changes, abdominal distension, muscle wasting, and a range of metabolic complications that can diminish quality of life and complicate comorbidities.

Given the variability of clinical manifestations and the potential overlap with iatrogenic causes such as chronic glucocorticoid therapy, accurate diagnosis requires integration of history, physical findings, biochemical screening tests, and confirmatory endocrine assays. Diagnostic accuracy and timely therapeutic intervention greatly influence clinical outcomes. For many practitioners, the decision tree between medical management and surgical intervention hinges on etiology, patient comorbidities, owner preferences, and access to specialized veterinary surgical services. Consequently, stakeholders across the pharmaceutical supply chain, veterinary clinics, and distribution networks need an informed, clinically grounded perspective to prioritize R&D, optimize therapy access, and support informed clinical decision-making.

This report's introductory framing underscores the intersection of clinical science, therapeutic options, and commercial dynamics that together shape treatment pathways for affected dogs. By aligning clinical imperatives with operational realities, stakeholders can better appreciate where innovation, improved delivery formats, and education will most effectively reduce diagnostic delay and improve long-term management.

How diagnostic advances, therapeutic refinements, and digital care models are reshaping the treatment landscape for dogs living with Cushing's disease

The landscape for treating Cushing's disease in dogs is undergoing several transformative shifts driven by advances in diagnostics, evolving therapeutic approaches, and changes in how owners engage with veterinary care. In diagnostics, improved assay sensitivity and wider availability of endocrine testing have shortened time-to-diagnosis for many patients, while cross-disciplinary collaboration between internal medicine specialists and diagnostic laboratories has standardized interpretive frameworks. At the same time, pharmaceutical innovation is shifting toward refined formulations and dosing strategies that improve tolerability and adherence, with a growing emphasis on evidence-based therapeutic protocols that balance efficacy and safety for long-term management.

Concurrently, the digital transformation of veterinary practice is reshaping care delivery. Telemedicine platforms, remote monitoring, and digital adherence tools are enabling more frequent clinician-owner touchpoints, thereby improving follow-up and dose adjustments. This trend is complemented by growth in e-commerce and online pharmacies, which are altering distribution economics and expanding access to oral therapeutics while creating new regulatory and quality control considerations. Furthermore, heightened owner expectations for personalized care have catalyzed interest in individualized treatment plans, including a more nuanced selection between medical therapy and surgical options based on risk-benefit profiles.

In addition, regulatory attention to pharmacovigilance and companion animal safety is fostering more rigorous post-approval monitoring and data transparency. Together, these shifts-better diagnostics, refined therapeutics, digital care models, and stronger post-market oversight-are converging to create a more patient-centric and data-rich environment for managing canine Cushing's disease, while also raising the bar for manufacturers and providers to demonstrate real-world value.

Assessment of how tariff adjustments can reverberate through pharmaceutical supply chains, distribution networks, and clinical access pathways for canine endocrine therapeutics

Trade policy developments, including tariff adjustments, can have a tangible ripple effect across the veterinary therapeutics ecosystem, and a comprehensive assessment of cumulative impacts emphasizes supply chain resilience, cost pass-through dynamics, and distribution adjustments. Changes in import duties that affect active pharmaceutical ingredients, finished formulations, packaging materials, or ancillary devices can increase procurement complexity for manufacturers and contract manufacturers that rely on multinational suppliers. As a result, procurement teams may re-evaluate supplier portfolios, prioritize domestic or regional sources, and renegotiate long-term contracts to buffer volatility.

These procurement shifts often translate into changes further along the value chain. Veterinary clinics and retail channels may encounter altered product availability or lead times, which can influence inventory practices and clinical decision-making, particularly for chronic therapies where continuity of dosing matters. In parallel, online pharmacies and cross-border distributors may face compliance and administrative burdens that slow fulfillment or increase transactional costs. Pricing pressures could lead stakeholders to revisit packaging configurations, explore local compounding where permissible, or accelerate formulation innovations that reduce reliance on constrained inputs.

Importantly, tariff-induced cost pressures can also intensify strategic collaboration between manufacturers and distributors to identify efficiency gains and to adapt commercial terms in ways that preserve patient access. Risk mitigation strategies include diversifying supplier geographies, investing in forward inventory planning, and strengthening contractual safeguards. Policymakers and industry participants should therefore monitor tariff policy closely and prepare contingency plans that preserve therapeutic continuity for patients while maintaining commercial viability for manufacturers and distributors.

Insight-driven segmentation analysis linking drug classes, treatment modalities, administration routes, and distribution channels to clinical and commercial priorities

Segment-level clarity is essential to understand therapeutic dynamics and to align commercial strategies with clinical use patterns. Based on drug class, therapeutic options are evaluated across ketoconazole, mitotane, and trilostane, each representing distinct mechanisms of action, safety profiles, and implications for long-term monitoring. Based on treatment type, decision-making maps onto medical therapy and surgical options; medical management encompasses the pharmaceutical agents ketoconazole, mitotane, and trilostane, whereas surgical care is characterized by adrenalectomy and hypophysectomy procedures that require specialized surgical expertise and perioperative support. Based on administration route, delivery channels include injectable and oral formats; injectable administration further differentiates into intramuscular and intravenous modalities, while oral dosing typically takes the form of capsules and tablets with implications for palatability, dosing accuracy, and owner adherence. Based on distribution channel, availability and access are governed by online pharmacies, retail pharmacies, and veterinary clinics, each channel presenting unique regulatory, logistical, and customer-experience considerations.

Taken together, these segmentation lenses expose where commercial opportunity and clinical need intersect. Drug-class distinctions matter to formulary decision-makers because each agent's pharmacodynamics, monitoring burden, and safety considerations influence both prescribing patterns and product positioning. Treatment-type segmentation underscores the divergent infrastructure and training needs associated with surgical care versus long-term medical management. Administration-route differences affect product development priorities such as creating palatable, sustained-release, or precision-dosed oral forms, and distribution-channel segmentation highlights the necessity of multi-channel strategies to balance clinical immediacy, price sensitivity, and adherence support.

Strategic planning that integrates these segment perspectives will be better positioned to tailor value propositions, design targeted education for clinicians and owners, and refine supply chain approaches that ensure timely access across the range of therapeutic pathways.

Regional dynamics and healthcare infrastructure differences that influence diagnostic access, treatment adoption, and distribution strategies across global veterinary markets

Geography remains a primary determinant of care delivery models, regulatory environments, and commercial dynamics, and understanding regional variation is critical for operational planning. In the Americas, mature veterinary infrastructures, widespread clinical networks, and growing pet insurance adoption support relatively high standards of diagnostic access and ongoing chronic disease management; at the same time, competitive distribution channels and sophisticated e-commerce ecosystems facilitate alternative procurement pathways for owners and clinics. In Europe, Middle East & Africa, regulatory heterogeneity and variable per-capita veterinary resources create diverse market conditions where urban centers often lead in access to specialized surgical services while rural areas rely more heavily on medical management and compounding services; regulatory harmonization initiatives and cross-border veterinary collaborations are shaping how manufacturers approach market entry and post-market surveillance in the region. In the Asia-Pacific region, rapid growth in pet ownership, urbanization, and rising disposable incomes have expanded demand for advanced veterinary care, yet disparities in clinical capacity and logistics infrastructure persist, which influences the relative uptake of oral therapeutics versus surgical interventions and drives innovation in telemedicine and online distribution.

Regional differences also inform supply chain and service models. For example, manufacturers and distributors may choose to localize certain production activities or to partner with regional logistics providers to mitigate lead-time variability. Clinical training programs and continuing education offerings must be tailored to regional clinical competencies and surgical availability. Ultimately, a regionally adaptive approach that recognizes distinct regulatory, cultural, and infrastructural realities will be more effective at ensuring consistent patient outcomes while enabling sustainable commercial operations across multiple geographies.

Competitive dynamics and strategic priorities for companies balancing therapeutic optimization, clinician partnerships, and distribution resilience in veterinary care

Competitive dynamics in therapeutic management of canine Cushing's disease reflect a balance between established pharmaceutical agents, evolving formulation strategies, and service-oriented differentiation. Companies operating in this space are focused on optimizing product attributes such as tolerability, dosing convenience, and stability, and they are increasingly investing in supporting assets like educational programs, clinical decision tools, and patient adherence platforms that complement core therapies. Moreover, some industry participants are pursuing formulation innovations that enhance palatability or enable more precise dosing for small patients, thereby addressing common barriers to adherence in a population with frequent comorbidities.

At the same time, surgical service providers and specialty clinics that offer adrenalectomy and hypophysectomy influence treatment-choice dynamics by shaping referral patterns and perioperative pathways. Collaboration between pharmaceutical firms and surgical centers can accelerate integrated care models that align medical management with clearly defined surgical indications. Additionally, contract manufacturing organizations and regional compounding pharmacies play a role in the supply ecosystem, particularly when demand for alternative preparations emerges. As the sector evolves, strategic priorities for companies include strengthening real-world evidence programs to demonstrate safety and comparative performance, expanding clinician education to support appropriate prescribing and monitoring, and exploring partnerships that enhance distribution resilience and broaden access across both traditional and digital channels.

Practical, cross-functional actions for manufacturers and service providers to enhance patient outcomes, supply resilience, and commercial effectiveness in veterinary therapeutics

Industry leaders seeking to improve care for dogs with Cushing's disease and to strengthen commercial outcomes should pursue a set of coordinated actions that span product, service, and operational domains. First, prioritize investment in clinician education and decision-support tools to reduce diagnostic delay and to foster evidence-based selection between medical and surgical pathways; these activities will simultaneously drive appropriate utilization and reinforce the safety profile of therapies. Second, diversify sourcing and logistics arrangements to mitigate exposure to trade policy shifts and supply disruptions, including establishing multi-sourced supply agreements and evaluating regional production or contract manufacturing options where feasible.

Third, design patient-centric product enhancements that improve palatability, dosing accuracy, and adherence tracking, while exploring digital therapeutics or companion apps that facilitate remote monitoring and owner engagement. Fourth, adopt a channel-inclusive commercial strategy that addresses the distinct needs of veterinary clinics, retail pharmacies, and online pharmacy platforms, ensuring that regulatory compliance, cold-chain requirements, and product information are consistent across touchpoints. Fifth, build robust real-world evidence and pharmacovigilance programs to demonstrate long-term safety and to inform label expansions or new formulation approvals. Finally, engage proactively with policymakers and professional associations to help shape pragmatic regulatory frameworks for veterinary therapeutics and to support standardized outcome measures that can be used across clinical studies and post-market surveillance.

Taken together, these recommendations help companies move from reactive tactics to a proactive agenda focused on clinical value, supply resilience, and sustained access for patients.

Robust mixed-methods research design combining clinician interviews, regulatory review, and data triangulation to validate trends and practical implications for care delivery

The research approach integrates qualitative and quantitative methods to ensure analytical rigor and practical relevance. Primary research included structured interviews with practicing veterinarians, specialty surgeons, diagnostic laboratory directors, and distribution partners to capture front-line perspectives on diagnosis, treatment selection, and access barriers. Secondary research drew on peer-reviewed veterinary literature, clinical guideline documents, regulatory agency publications, and publicly available clinical trial registries to synthesize established clinical knowledge and to contextualize emerging therapeutic practices.

Data synthesis involved triangulation across sources to validate trends and reconcile differences between reported practices and observed behaviors in clinics and distribution channels. Where applicable, case studies were developed to illustrate how supply chain disruptions, regulatory changes, or clinical innovations impacted care delivery in specific regional contexts. Limitations of the methodology include inherent variability in clinical practice across geographies and the evolving nature of digital care models, which may outpace available published evidence. To address these limitations, findings were corroborated through iterative expert consultations and by cross-checking with multiple independent data points to enhance reliability and to surface practical implications for stakeholders.

Concluding synthesis emphasizing the need for integrated clinical, commercial, and operational strategies to improve outcomes for dogs with Cushing's disease

In conclusion, treating Cushing's disease in dogs sits at the intersection of endocrinology, pharmacology, and clinical service delivery, and progress in this space depends on aligning clinical innovation with operational execution. Diagnostic improvements and therapeutic refinements are creating opportunities to improve long-term outcomes, but realizing that potential requires coordinated efforts across manufacturers, distributors, clinics, and regulatory stakeholders. Supply chain resilience and adaptive distribution strategies will be essential as trade policy or sourcing disruptions arise, while targeted clinician education and patient-centered product design can reduce barriers to adherence and enhance quality of life for affected animals.

Ultimately, the most effective responses will be those that recognize the heterogeneity of clinical pathways-medical therapy versus surgery, oral versus injectable administration-and that tailor solutions to regional realities and stakeholder needs. By integrating clinical evidence, commercial strategy, and operational preparedness, stakeholders can better ensure consistent access to safe and effective therapies and support improved outcomes for dogs living with Cushing's disease.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Treating Cushing's Disease in Dogs Market, by Drug Class

  • 8.1. Ketoconazole
  • 8.2. Mitotane
  • 8.3. Trilostane

9. Treating Cushing's Disease in Dogs Market, by Treatment Type

  • 9.1. Medical
    • 9.1.1. Ketoconazole
    • 9.1.2. Mitotane
    • 9.1.3. Trilostane
  • 9.2. Surgical
    • 9.2.1. Adrenalectomy
    • 9.2.2. Hypophysectomy

10. Treating Cushing's Disease in Dogs Market, by Administration Route

  • 10.1. Injectable
    • 10.1.1. Intramuscular
    • 10.1.2. Intravenous
  • 10.2. Oral
    • 10.2.1. Capsules
    • 10.2.2. Tablets

11. Treating Cushing's Disease in Dogs Market, by Distribution Channel

  • 11.1. Online Pharmacies
  • 11.2. Retail Pharmacies
  • 11.3. Veterinary Clinics

12. Treating Cushing's Disease in Dogs Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Treating Cushing's Disease in Dogs Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Treating Cushing's Disease in Dogs Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Treating Cushing's Disease in Dogs Market

16. China Treating Cushing's Disease in Dogs Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Bayer AG
  • 17.6. Bimeda, Inc.
  • 17.7. Boehringer Ingelheim Animal Health USA Inc.
  • 17.8. Ceva Sante Animale
  • 17.9. Chanelle Pharma Group
  • 17.10. Covetrus, Inc.
  • 17.11. Dechra Pharmaceuticals PLC
  • 17.12. Elanco Animal Health Incorporated
  • 17.13. Heska Corporation
  • 17.14. IDEXX Laboratories, Inc.
  • 17.15. Kyoritsu Seiyaku Corporation
  • 17.16. Merck & Co., Inc.
  • 17.17. Nippon Zenyaku Kogyo Co., Ltd.
  • 17.18. Vetoquinol S.A.
  • 17.19. Virbac SA
  • 17.20. Vetoquinol
  • 17.21. Zoetis Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL TREATING CUSHING'S DISEASE IN DOGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL TREATING CUSHING'S DISEASE IN DOGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY KETOCONAZOLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY KETOCONAZOLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY KETOCONAZOLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY MITOTANE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY MITOTANE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY MITOTANE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY TRILOSTANE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY TRILOSTANE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY TRILOSTANE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY MEDICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY MEDICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY MEDICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY MEDICAL, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY KETOCONAZOLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY KETOCONAZOLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY KETOCONAZOLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY MITOTANE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY MITOTANE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY MITOTANE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY TRILOSTANE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY TRILOSTANE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY TRILOSTANE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY SURGICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY SURGICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY SURGICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY ADRENALECTOMY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY ADRENALECTOMY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY ADRENALECTOMY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY HYPOPHYSECTOMY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY HYPOPHYSECTOMY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY HYPOPHYSECTOMY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY VETERINARY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY VETERINARY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY VETERINARY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY MEDICAL, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY MEDICAL, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 88. LATIN AMERICA TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY MEDICAL, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE, MIDDLE EAST & AFRICA TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY MEDICAL, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY MEDICAL, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 115. MIDDLE EAST TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY MEDICAL, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 118. MIDDLE EAST TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. AFRICA TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 124. AFRICA TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY MEDICAL, 2018-2032 (USD MILLION)
  • TABLE 126. AFRICA TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY MEDICAL, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. ASEAN TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. ASEAN TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 143. ASEAN TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY MEDICAL, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 146. ASEAN TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 150. GCC TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. GCC TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 152. GCC TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. GCC TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY MEDICAL, 2018-2032 (USD MILLION)
  • TABLE 154. GCC TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 155. GCC TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 156. GCC TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 157. GCC TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 158. GCC TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPEAN UNION TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPEAN UNION TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPEAN UNION TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPEAN UNION TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY MEDICAL, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPEAN UNION TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPEAN UNION TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 168. BRICS TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. BRICS TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 170. BRICS TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. BRICS TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY MEDICAL, 2018-2032 (USD MILLION)
  • TABLE 172. BRICS TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 173. BRICS TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 176. BRICS TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 177. G7 TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. G7 TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 179. G7 TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. G7 TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY MEDICAL, 2018-2032 (USD MILLION)
  • TABLE 181. G7 TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 182. G7 TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 183. G7 TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 184. G7 TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 185. G7 TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 186. NATO TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. NATO TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 188. NATO TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. NATO TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY MEDICAL, 2018-2032 (USD MILLION)
  • TABLE 190. NATO TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 191. NATO TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 192. NATO TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 193. NATO TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 194. NATO TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 195. GLOBAL TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. UNITED STATES TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 197. UNITED STATES TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 198. UNITED STATES TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. UNITED STATES TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY MEDICAL, 2018-2032 (USD MILLION)
  • TABLE 200. UNITED STATES TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 201. UNITED STATES TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED STATES TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED STATES TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED STATES TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 205. CHINA TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 206. CHINA TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 207. CHINA TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. CHINA TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY MEDICAL, 2018-2032 (USD MILLION)
  • TABLE 209. CHINA TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 210. CHINA TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 211. CHINA TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 212. CHINA TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 213. CHINA TREATING CUSHING'S DISEASE IN DOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)